XOMA Royalty Corporation Stock Price, News & Analysis

XOMA Royalty (Nasdaq: XOMA) and LAVA Therapeutics (Nasdaq: LVTX) amended their share purchase agreement on October 17, 2025.

Under the Amendment, tendering LAVA shareholders will receive an initial cash amount of $1.04 per share plus a non-transferable CVR that preserves rights to 75% of net proceeds from partnered assets and unpartnered program exits, and a new contingent right of up to $0.23 per CVR depending on final liability determinations. LAVA’s minimum net-cash closing condition was reduced to $24.5 million (from $31.5 million). The Offer deadline extended to Nov 12, 2025 and closing is expected in Q4 2025, subject to tender thresholds and shareholder approvals.

XOMA Royalty (NASDAQ: XOMA) and LAVA Therapeutics (Nasdaq: LVTX) extended the expiration of their tender offer to acquire all outstanding LAVA shares until one minute after 11:59 p.m. ET on October 17, 2025. The Offer pays a cash amount (per the Purchase Agreement) plus a non-transferable CVR per share granting holders 75% of net proceeds from LAVA’s two partnered assets and 75% of net proceeds from any out-license or sale of unpartnered programs. Closing is expected in Q4 2025, subject to conditions including at least 80% (or 75%) tendered shares, shareholder approvals, a minimum cash balance at closing, and other customary conditions. LAVA shareholders have signed support agreements; a shareholder meeting is planned before early November 2025.

XOMA Royalty Corporation (NASDAQ: XOMA) has declared quarterly cash dividends for its preferred stockholders. The company will distribute dividends to two classes of preferred shares:

- Holders of 8.625% Series A Preferred Stock (NASDAQ: XOMAP) will receive $0.53906 per share
- Holders of 8.375% Series B Preferred Stock (NASDAQ: XOMAO) will receive $0.52344 per depositary share

Both dividends are scheduled for payment on October 15, 2025, to shareholders of record as of October 3, 2025.

XOMA Royalty (NASDAQ: XOMA) has successfully completed its tender offer to acquire HilleVax (NASDAQ: HLVX). The acquisition terms included $1.95 per share in cash plus one non-tradeable contingent value right (CVR).

The tender offer expired on September 15, 2025, with 39,214,689 shares validly tendered, representing approximately 77.48% of HilleVax's outstanding shares. Following the merger completion, HilleVax became a wholly owned subsidiary of XOMA Royalty. HilleVax shares will cease trading on Nasdaq as of September 17, 2025, and will be delisted and deregistered.

XOMA Royalty Corporation (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's leadership team, including CEO Owen Hughes and CIO Brad Sitko, will deliver a company update presentation on Monday, September 8, 2025, at 9:00 AM ET.

Investors can access the presentation through a webcast link or via the investor relations section of XOMA's website at www.xoma.com.

XOMA Royalty (NASDAQ:XOMA) has announced its subsidiary XRA 5 Corp. will acquire Mural Oncology (NASDAQ:MURA) in an all-cash transaction valued at approximately $36.2 million. Under the agreement, Mural shareholders will receive a base price of $2.035 per share, with potential for an additional $0.205 per share based on Mural's closing net cash position.

The base offer represents a 13.1% premium to Mural's closing price of $1.80 on August 19, 2025, and a 97.6% premium to its undisturbed price of $1.03 on April 14, 2025. The acquisition, recommended by Mural's board, follows a strategic review process and is expected to close by the end of 2025, subject to shareholder and regulatory approvals.

XOMA Royalty (NASDAQ:XOMA) reported Q2 2025 financial results and significant business developments. The company received $29.6 million in royalties and milestones in H1 2025, including $11.7 million in Q2. Notable achievements include the acquisition of multiple companies (Turnstone Biologics, LAVA Therapeutics, and HilleVax) and the $20 million purchase of mezagitamab royalty rights from BioInvent.

Q2 2025 financial highlights include net income of $9.2 million and total income/revenue of $13.1 million. The company ended Q2 with $78.5 million in cash and cash equivalents. Several pipeline advancements were reported, including Rezolute's completion of Phase 3 enrollment for ersodetug and EMA's acceptance of Day One's tovorafenib MAA.

[ "Received $29.6 million in royalties and milestones in H1 2025", "Net income of $9.2 million in Q2 2025, up from $7.4 million in Q2 2024", "Strategic acquisitions of Turnstone Biologics, LAVA Therapeutics, and HilleVax expanding portfolio", "Strong cash position of $78.5 million as of June 30, 2025", "Multiple pipeline advancements including regulatory milestones and Phase 3 trial progress", "Decreased G&A expenses to $7.8 million in Q2 2025 from $11.0 million in Q2 2024" ]

XOMA Royalty (NASDAQ: XOMA) has successfully completed its tender offer to acquire Turnstone Biologics (NASDAQ: TSBX). The deal terms included $0.34 per share in cash plus one non-tradeable contingent value right (CVR).

As of the expiration date on August 7, 2025, 17,192,002 shares were validly tendered, representing approximately 74% of Turnstone's outstanding shares. Following the tender offer, XOMA Royalty merged Turnstone with its subsidiary XRA 3 Corp., making Turnstone a wholly owned subsidiary. Turnstone's shares will cease trading on Nasdaq as of August 11, 2025, and will be delisted and deregistered.

XOMA Royalty (NASDAQ: XOMA) has entered into a definitive agreement to acquire LAVA Therapeutics (NASDAQ: LVTX) in a structured deal valued at $1.16 to $1.24 per share in cash, plus a contingent value right (CVR). The CVR entitles shareholders to 75% of net proceeds from LAVA's partnered assets and potential out-licensing of unpartnered programs.

The transaction, expected to close in Q4 2025, requires at least 80% shareholder tender and includes specific closing conditions. As part of the deal, LAVA will discontinue its Phase 1 clinical trial of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome. The acquisition adds milestone and royalty economics from LAVA's gamma delta bispecific antibodies portfolio to XOMA Royalty's assets.